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Abstract 
BACKGROUND: The cluster of differentiation (CD) 74 is known for its immunological functions and its elevated 
level was reported in various cancer cells.  
AIM: The aim of the present study was to investigate the expression and potential roles of CD74 in the 
proliferative and apoptotic activity of breast cancer.  
METHODS: Expression of CD74, macrophage migration inhibitory factor (MIF) and CD44 was assayed in CAMA-
1 and MDA-MB-231 cell lines using flow cytometry. CD74 was knocked down using CD74 siRNA-transfection in 
CAMA-1, and MDA-MB-231 cells and proliferation and apoptosis were determined in the transfected breast 
cancer cells.  
RESULTS: The data showed that CD74, MIF and CD44 were expressed in breast cancer cell lines and were 
associated with cell proliferation and apoptosis. Correlation analysis revealed that CD74 was positively correlated 
and colocalised with MIF on the cell-surface of CAMA-1 and MDA-MB-231. The knockdown of CD74 significantly 
reduced CAMA-1 and MDA-MB-231 cell proliferation and increased the level of apoptotic cells. 
CONCLUSION: We concluded that the interactions of CD74 with MIF and CD74 with CD44 could be a potential 
tumour marker for breast cancer cells. Moreover, the level of co-expression of MIF and CD74 or CD44 could be a 
surrogate marker for the efficacy of anti-angiogenic drugs, particularly in breast cancer tumours. In short, the 
study revealed the potential roles of CD74 in the proliferation and apoptosis of breast cancer which may serve as 
a potential therapeutic target for breast cancer. 
 
 
 
Introduction 
 
The role of a cluster of differentiation (CD) – 
74 is a transmembrane glycoprotein, and its role has 
recently been reported in the pathogenesis of several 
cancers including breast cancer [1], [2]. Several 
studies have suggested that a small proportion of 
intracellular CD74 is modified by the addition of 
chondroitin sulfate (CD74-CS), a form of CD74 and 
chondroitin sulfate is a sulfated glycosaminoglycan 
usually found attached to proteins as part of a 
proteoglycan [3], [4]. CD74-CS is expressed on the 
surface of immune cells and can bind MIF, mediating 
MIF’s signalling pathway [3], [4]. Cell-surface 
expression of CD74 is not strictly dependent on the 
expression of class II MHC molecules in term of 
antigen presentation [5], [6] and numerous non-class 
II positive cells express CD74 which functions as a 
receptor for the initiation of different signalling 
cascades [7], [8]. MIF is the natural ligand of CD74 
and binds to the extracellular domain of CD74 with 
high affinity (KD = 1.40 Å ~ 10-9 M) and initiates a 
signalling cascade [9]. When bound to the 
extracellular domain of CD74, MIF promotes signalling 
pathways including cell proliferation and apoptosis [9], 
[10], [11], [12], [13]. The short cytoplasmic tail of 
CD74 lacks an intracellular signal-transducing 
domain, although serine phosphorylation takes place 
in the P35 variant of CD74, requiring CD44, a 
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polymorphic transmembrane protein with kinase 
activating properties [14], [15]. CD74 forms a complex 
with CD44 which is essential for the MIF-induced 
signalling cascade [10], [16]. This cascade induces 
phosphorylation of ERK1 and ERK2 and activates 
various effector proteins involved in inflammatory 
processes and cell proliferation. ERK1 and ERK2 
remain phosphorylated for many hours and hence this 
cascade continues for up to 2 to 3 hours [17], [18], 
[19], [20], [21]. Concurrently, MIF binding to CD74 
activates the P13K-Akt pathway leading to 
phosphorylation of BAD and BAX proteins which are 
involved in apoptosis [22]. In addition, this cascade 
augments Bcl-2 expression, further supporting cell 
survival [23], [24], [25]. Thus, the binding of MIF to the 
CD74 / CD44 complex initiates a pathway resulting in 
the proliferation of the mature B cell population and 
their rescue from cell death. In addition to activating 
the P13K-Akt pathway, MIF binding to CD74 also 
induces a signalling pathway which involves Syk 
tyrosine kinase [6], [16] and induces cleavage of 
intramembrane CD74 regional releases intracellular 
domain (CD74-ICD) [26], [27]. CD74-ICD translocates 
to the nucleus where it induces activation of 
transcription mediated by the NF-κB p65 / RelA 
homodimer and its co-activator, TAFII105, resulting in 
regulation of transcription of genes that control B cell 
proliferation and survival [3], [6], [16]. Therefore, the 
CD74-MIF-CD44 complex initiates a pro-survival 
signal leading to the increase of proliferation and 
inhibition of apoptosis. 
Recently, we quantified colocalization of 
CD74 and CD44 in breast cancer cells through non-
invasive and validated bioimaging procedure [28] and 
also determined several novel biomarkers involved in 
the pathogenesis of breast cancer [29]. Not only have 
these, but we also showed that treatment of human 
breast cancer cells with interferon-γ up-regulates the 
expression of CD74 along with MIF and CD44 [2], 
[30]. In continuation of these studies, the present 
study was hypothesised to find out the potential roles 
of CD74 in the proliferative and apoptotic activity in 
breast cancer. This was achieved by studying the 
colocalization of CD74 and MIF as well as CD74 and 
CD44 by two different techniques confocal microscopy 
and immunoprecipitation. The cells proliferation and 
apoptosis in CD74 siRNA transfected cells were also 
studied to address the hypothesis that blocking CD74 
or MIF would affect apoptosis and cell proliferation. 
 
 
Methods  
 
Cell lines and cell culture 
Two human mammary gland cell lines, 
CAMA- 1 and MDA-MB-231, were used, which were 
derived from a malignant pleural effusion. The CAMA-
1 cell lines were maintained in RPMI 1640 medium 
(LONZA-Belgium), supplemented with 10% (v / v) fetal 
calf serum (FCS; Imperial Laboratories, Andover, UK). 
The MDA-MB-231 cell line was maintained in D-MEM 
(high glucose), supplemented with 10% FCS. Raji 
cells (human negroid Burkitt’s lymphoma) and HeLa 
cells (human cervical cancer), expressing high levels 
of CD74, MIF, and CD44, respectively, served as 
additional positive controls. Raji and HeLa cells were 
cultured in RPMI 1640 (LONZA-Belgium) containing 
10% FCS and cultured in a humidified atmosphere of 
5% CO2at 37°C. All media used for this study were 
purchased from PAA Laboratories GmbH (Pasching, 
Austria). 
 
Flow cytometry analysis 
Cell lines were lifted with Accutase (Sigma-
Aldrich), and 1 x 10
6
cells were used per sample. 
Monoclonal primary antibodies, By2 (anti-CD74), 
ab55445 (anti-MIF) and 156-3c11 (anti-CD44) were 
employed in indirect immunofluorescence staining. 
Cells were preincubated with saturating 
concentrations of primary antibody, followed by 
washing and labelling with FITC-conjugated goat anti-
mouse IgG (Bio-legend). For cell surface staining, 
cells were fixed with 4% formaldehyde solution and 
washed with 1X phosphate-buffered saline (PBS). The 
cells were then blocked with blocking buffer (PBS / 
0.1% BSA, bovine serum albumin) and washed in 
PBS. Primary and secondary antibodies were diluted 
with 0.1% BSA in PBS. Cells were sorted on a BD 
FAS Aria and analysed by FlowJo 8.8.6. 
 
Immunofluorescence 
In preparation for confocal 
immunofluorescence microscopy for studying 
colocalization between CD74 and MIF, CAMA-1 and 
MDA-MB-231 cells were cultured in LabTek 8-well 
chambers (Thermo Fisher Scientific) at a density of 6 
x 10
3
cells per well for two days. Following this, they 
were seeded. The cells were fixed with 4% 
paraformaldehyde for 20 min on ice. Cells were then 
blocked with 2% (w / v) BSA prepared in 1X PBS for 1 
h at room temperature. For single staining of each 
antigen, cells were incubated with anti-CD74 (clone: 
By2) at a concentration of 1:500, (anti-MIF) (clone: 
ab55445) and 156-3c11 (anti-CD44) at a 
concentration of 1:400 for 1 h, followed by three 
washes with PBS. Secondary antibody, anti-mouse 
IgG conjugated with Alexa Fluor® 488 or Alexa Fluor® 
555 (Invitrogen, Carlsbad, CA, USA), was used at a 
dilution of 0.25 μg / 100 ml for 1 h. For double 
staining, cells were blocked again with 2% BSA and 
the staining process was repeated for each desired 
pair. Cells were thoroughly washed with PBS, the 
chambers removed, and the slide was mounted with 
anti-fade mounting medium (Vector Shield) covered 
with a coverslip (Chance proper LTD, West Midlands, 
England) and sealed with rubber cement (Fixogum 
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Rubber Cement, Marabu, Germany). Cells were 
incubated with a primary antibody followed by a 
secondary antibody. CD74 was labelled with FITC 
Alexa Fluor 488 (green) and CD44 was labelled with 
Alexa Flour 555 (red). Colocalization of CD74 with 
CD44 was assessed by Pearson’s correlation 
coefficient was used to analyze the degree of 
colocalization. The scale lay between -1 and 1, where 
1 stand for colocalization, -1 stands for negative 
colocalization and 0 stands for no colocalization. 4’, 6-
diamidino-2-phenylindole dihydrochloride (DAPI) 
counterstain (Vector Laboratories, Burlingame, CA, 
USA) was used at a 1:250 dilution. 
 
Quantitative colocalization analysis of 
 confocal fluorescence microscopy images  
To investigate whether CD74 and MIF co-
localize, a high-precision single-cell bioimaging 
protocol was employed, previously developed by our 
research group [31]. The Pearson correlation 
coefficient (PCC) was used for quantitative analysis of 
colocalization [31], [32]. PCC provides the overall 
association of two probes in an image, statistically. It 
also indirectly measures the quantity, i.e. the fraction 
of one protein that colocalises with another protein. A 
Nikon A1Si confocal microscope (Nikon Instruments 
Inc.) with a plan-apochromatic VC1.4 N.A. 60X 
magnifying oil-immersion objective was used for 
image acquisition. Images were acquired in three 
channels, using one-way sequential line scans. DAPI 
was excited at 398.7 nm with laser power 1.6 arbitrary 
units, and its emission was collected at 450 nm with a 
PMT gain of 86. Alexa Fluor 488 was excited at 488 
nm with laser power 5.8; its emission was collected at 
525 nm with a PMT gain of 117. Alexa Fluor 555 was 
excited at 560.5 nm with laser power 3.7, and its 
emission was collected at 595 nm with a PMT gain of 
98. The scan speed was ¼ frames/s (Galvano 
scanner). The pinhole size was 35.76 μm, 
approximating 1.2 times the Airy disk size of the 1.4- 
NA objective at 525 nm. Scanner zoom was centred 
on the optical axis and set to a lateral magnification of 
60 nm/pixel. Axial step size was 105 nm, with 80-100 
image planes per z-stack. 
 
Small interfering (si) RNA transfection 
CAMA-1 and MDA-MB-231 cell lines were 
seeded in six-well plates at a density of 2 × 10
5
 per 
well in 2 ml normal growth medium supplemented with 
10% FCS. The cells were then allowed to grow until 
they reached 60-80% confluency. For each 
transfection, 4 µl of CD74 siRNA duplex at dose of 80 
pmols (sc-35023) (Santa Cruz Biotechnology, USA) 
was diluted and 4 µl of siRNA transfection reagent 
was added at dose of 80 pmols (sc-29528) (Santa 
Cruz Biotechnology, USA) into 100 µl of siRNA 
transfection medium (sc-36868) (Santa Cruz 
Biotechnology, USA) separately without serum or 
antibiotics. Both diluents were mixed and incubated 
for 15-45 minutes at room temperature. Cells were 
then washed with 2 ml of siRNA transfection medium. 
The siRNA transfection reagent mixture was then 
added to each well, and the volume made up to 1 ml 
by adding 800 µl of siRNA transfection medium (Santa 
Cruz Biotechnology, USA). In the same manner, this 
was applied for negative control siRNA (sc-44230) 
(Santa Cruz Biotechnology, USA). The cells were then 
incubated overnight at 37ºC in a CO2 incubator for 18-
24 hr. Following incubation, the medium was 
aspirated and replaced with fresh 1X normal growth 
medium. Cells were assayed using the appropriate 
manufacturer’s protocol 24-72 hours after the addition 
of fresh medium in the step above. Transfection 
efficiency was confirmed by western blot and 
microscopy. Once the transfection was confirmed, the 
effect of CD74 siRNA on the proliferation and 
apoptosis of CAMA-1 and MDA-MB-231 could then be 
studied. 
 
Proliferation and Apoptosis assay 
CAMA-1 and MDA-MB231 cell lines were 
cultured in 6 well plates at a density of (15 × 10
3
 
cell/well) or in 96 well plates at a density of (15 × 10
2
 
cell/well) at 37°C and then transfected with CD74 
siRNA duplex as explained previously. The cells were 
then washed twice with 1X PBS and incubated with 2 
µl of Annexin V-FITC (BioLegend, UK) at room 
temperature for 20 minutes in the dark. Cells were 
then thoroughly washed and then fixed with 4% PFA 
followed by washing steps in PBS. Finally, the 
samples were read using BD FACSAria and analysed 
by FlowJo 8.8.6. In the same manner, the MTT assay 
was then used to assess cell proliferation. Briefly, 20 
µl of MTT solution (5 mg/ml in PBS) and 100 µl was 
added per well, and cells were incubated at 37°C with 
5% CO2 in a humidified chamber for 4 hr for colour 
development. The resultant Formazan crystals were 
dissolved in dimethyl sulfoxide (100 µl) and the 
absorbance intensity measured at 595 nm using a 
microplate reader (Versamax). The percentage of cell 
proliferation was calculated relative to the rate of 
proliferation in untreated cells. 
 
 
Results  
 
Cell-surface expression of CD74, MIF and 
 CD44 
The cell-surface expression of CD74, MIF and 
CD44 were analysed in CAMA-1, MDA-MB-231. Non-
permeabilized were stained with an appropriate 
concentration of By2 (anti-CD74), ab55445 (anti-MIF) 
and 156-3C11 (anti-CD44) antibodies followed by 1 μl 
RAM-FITC secondary antibody. Cells without staining 
and isotype cells, stained with only secondary 
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antibody, were used as a negative control. CD74, MIF 
and CD44 expression were detected on the cell 
surface and cytoplasmic of CAMA-1 and MDA-MB-
231. Monocytes, Raji cells, cervical cancer HeLa cells, 
and lymphocytes, (Jurkat) cells, were used as a 
positive control as they express high levels of CD74, 
CD44, and MIF respectively. This is displayed in 
Figure 1 in where empty histograms show CD74, MIF 
or CD74 protein grey filled the histogram. 
 
Figure 1: Flow cytometric analysis for cell surface expression of 
CD74, MIF and CD44 in the breast cancer cells displayed; Empty 
histograms represented the expression of CD74, MIF, and CD44; 
Expression in Raji, Jurkat, and HeLa cells are used positive controls. 
Whereas, grey-filled histograms were shown as a negative control 
obtained from isotype-matched with control antibody; The data are 
representative of three independent assays 
 
Colocalization of MIF with CD74and CD44 
To investigate whether MIF colocalised with 
CD74 or CD44 on CAMA-1 and MDA-MB-231 cells, 
all cell lines were immunostained with an appropriate 
primary antibody followed by a secondary antibody 
(Figure 2 and Figure 3). 
 
Figure 2: Figure 2: Colocalization of MIF and CD44 on the cell-
surface of CAMA-1 and MDA-MB-231 cells, determined by confocal 
microscopy analysis; CAMA-1 and MDA-MB-231 and MDA-MB-435 
cells were cultured in LabTek 8-well chambers at a density of 10 × 
103 cells per well overnight; The cells were stained with MIF 
labelled with Alexa Fluor® 488 (green) or CD44 labelled with Alexa 
Fluor® 555 (red); Cell nuclei were stained with 4', 6-diamidino-2-
phenylindole (blue); Fluorochromes were acquired separately to 
evaluate the expression of CD44 and MIF; Yellow/orange 
fluorescence reveals the potential colocalization of two antigens. 
The images represent three different experiments 
CD74 or CD44 was labelled with Alexa Fluor® 
(red) and MIF Alexa Fluor® (green). CAMA-1 and 
MDA-MB-231 cells showed clear expression of MIF, 
CD74, and MIF. Merging green and red channels 
assessed the colocalization and Pearson’s product-
moment correlation coefficient (PCC) was used to 
analyse the degree of colocalization. 
 
Figure 3: Figure 3: Colocalization of CD74 and MIF on the cell-
surface of CAMA-1 and MDA-MB-231 cells, determined by confocal 
microscopy analysis; A) CAMA-1 and MDA-MB-231 cells were 
cultured in LabTek 8-well chambers at a density of 10 × 103 cells 
per well overnight; Cells were stained with MIF labeled with Alexa 
Fluor® 488 (green) or CD74 labeled with Alexa Fluor® 555 (red); 
Cell nuclei were stained with 4', 6-diamidino-2-phenylindole (DAPI) 
(blue); Fluorochromes were acquired separately to evaluate the 
expression of CD74 and MIF; Yellow / orange fluorescence reveals 
the potential colocalization of the two antigens; 3D images were 
acquired in the stack, with z-direction step size 0.14 μm using NIS 
element; Single-plane of z-stack is shown in three directions as xy, 
yz and zx; Data represent three different experiments; B) Each pixel 
in the image was plotted in the scatter diagram based on its 
intensity level in each channel; The color in the scatterplot 
represents the number of pixels plotted in that region; In this 
example, green is shown on the x-axis and red is shown on the y-
axis; The scatterplot shows high colocalization and no bleed 
through either green or red channels; The scatter plot provides the 
rate of the area of association of two fluorochromes, calculated by 
linear regression; The scatter plot comprised of dots, appearing as 
cloud, indicates complete colocalization; B) Graphical 
representation of colocalization analysis based on the Pearson 
product-moment correlation coefficient (PCC) on each cell; The 
value for PCC ranges from +1 and −1 inclusive; A value of +1 would 
mean the total positive correlation, every pixel that contains Alexa 
Fluor® 488 (FITC) also contains Alexa Fluor® 555 (TRITC), while a 
value of −1 would mean the total negative correlation, every pixel 
that contains Alexa Fluor® 488 does not contain Alexa Fluor® 555 
and vice versa; The PCC was calculated based on different images 
and indicates strong colocalization of CD74 and MIF on CAMA-1 
and MDA-MB-231 Data represents three different experiments 
 
Knockdown of CD74 expression in CAMA-
 1 and MDA-MB-231 cells by CD74 siRNA  
Prior studies have reported that CD74 is over-
expressed in human breast adenocarcinomas, and 
has a role in tumour progression along with MIF and 
CD44. The expression of CD74 in CAMA-1 and MDA-
MB-231 cells was therefore evaluated. The 
expression of CD74 was found to be highest in 
CAMA-1 cells compared to MDA-MB-231 cells (Figure 
4). In pilot experiments, it was found that a 
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concentration of 80 pmol/ml for 24 hr of specific CD74 
siRNA was optimal for disrupted expression of CD74. 
Therefore, a dose of 80 pmol/ml was selected for 
optimal transfection of CAMA-1 and MDA-MB-231 
cells with siRNA for all subsequent experiments.  
 
Figure 4: Figure 4: CD74 knockdown by CD74 siRNA transfection 
reagent in CAMA-1 and MDA-MB-231 cells; A) and B) siRNA-
mediated knockdown of CD74 expression in CAMA-1 and MDA-
MB-231 cells were detected by Western blot; An approximately two 
to five (siRNA) fold weaker signal of CD74 protein expression is 
apparent, as compared to the negative control siRNA group 
normalized to the expression of α-Tubulin; C) and D) Confocal 
images of CAMA-1 and MDA-MB-231 cells transfected with CD74 
siRNA, untreated control and negative control siRNA; Data 
represent three different experiments 
 
 
Knockdown of functional CD74 expression 
 in CAMA-1 and MDA-MB-231 cells 
 promotes apoptosis 
In the light of the observations indicating 
apoptotic modes of cell death in CAMA-1 and MDA-
MB-231 cells treated with CD74 siRNA next, multi-
parameter flow cytometric analysis of siRNA-
transfected CAMA-1 and MDA-MB-231 cells was 
pursued to obtain more sensitive and quantitative 
details of a possible apoptotic mode of cell death. 
Following 24 hr of a culture of CD74 siRNA-
transfected CAMA-1 and MDA-MB-231 cells, flow 
cytometry was used to detect the expression of 
annexin V in the absence of PI staining.  
Annexin V is a non-quantitative probe used to 
detect phosphatidylserine expressed on the cell 
surface, an indication of apoptosis. CAMA-1 and 
MDA-MB-231 cells treated with CD74 siRNA 
displayed significantly higher levels of annexin V 
staining (± 55% and 58% respectively) compared with 
negative control siRNA-treated counterparts (± 8% 
and ± 13% respectively) (Figure 5A). These 
observations indicate that CD74 might play important 
regulatory roles in apoptosis. 
 
 
 
Effects of CD74 knockdown on CAMA-1 
 and MDA-MB-231 cell proliferation 
CAMA-1 and MDA-MB-231 cell proliferation 
and viability were determined using the MTT 
metabolic and viability assay (Figure 5B). CAMA-1 
and MDA-MB-231 cells treated with CD74 siRNA 
displayed significantly reduced proliferation compared 
to cells treated with the negative control siRNA control 
sequence. 
 
Figure 5: Figure 5: Effect of CD74 siRNA on the apoptosis and 
proliferation of CAMA-1 and MDA-MB-231 cells; A) Flow cytometric 
determination of the effect of CD74 siRNA on apoptosis of CAMA-1 
and MDA-MB-231 cells; Cultured CAMA-1 and MDA-MB-231 cells 
were divided into three groups: nontransfected cells, cells 
transfected with negative control siRNA and cells transfected with 
CD74 siRNA; After a 24 hr treatment, the cells were harvested for 
quantitation of apoptosis by determining changes in the cell-surface 
expression of annexin V; Displayed is also a description of the 
observed frequency of cells undergoing apoptosis, which was found 
to be much higher in the CD74 siRNA treated cells than in the 
negative control-treated group of CAMA-1 and MDA-MB-231 cells, 
respectively; B) Effect of CD74 siRNA on the proliferation of CAMA-
1 and MDA-MB-231 cells; MTT assay showed that treatment of 
CAMA-1 and MDA-MB-231 cells with CD74 siRNA inhibited their 
proliferation; Each point in the curve represents the arithmetic mean 
OD values ± SD from representative experiments that were 
performed in triplicate 
 
 
Discussion 
 
The present study aimed to investigate the 
role of CD74 and its interrelation to MIF in breast 
cancer cells. This was achieved by studying the 
expression and colocalization of MIF with CD74 and 
CD44 molecules in the breast cancer cell lines CAMA-
1 and MDA-MB-231 cells. The results obtained from 
confocal microscopy demonstrated that CD74 and 
MIF are highly colocalized on the cell-surface of all 
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breast cancer cells. Pearson’s correlation coefficient 
and scatter plot analysis (Figure 3) also gave rise to 
the colocalization of CD74 and MIF [33], which 
accurately depicts the percentage of colocalization of 
CD74 and MIF molecules. Several groups have 
studied the association of CD74 with MIF and CD44 in 
cancers since it was reported that CD74 and CD44 
are involved in signalling with MIF [10], [15], [16]. We 
also showed that CD74 and CD44 colocalise in breast 
cancer cells using a non-invasive and validated 
bioimaging procedure [28]. Also, it was shown that the 
formation of a molecular complex between MIF, CD74 
and CD44 in prostate carcinoma cells lines (DU-145) 
could mediate signal transduction including (gene 
regulation, apoptosis, and cell proliferation) in prostate 
cancer [34]. 
Previous studies by immunofluorescence 
have confirmed the colocalization of MIF and CD74 in 
non-small cell lung cancer [35]. Additionally, using 
correlation analysis, Zheng et al. identified a positive 
correlation between MIF and CD74 in gastric cancer 
cells [36]. Correspondingly, Starlets et al. showed 
that, in malignant B cells obtained from patients with 
chronic lymphocytic leukaemia (CLL), MIF binds to the 
extracellular domain of CD74 to initiate a signalling 
cascade leading to cell proliferation and survival [6]. 
The interaction of MIF with CD74 and CD44 has been 
reported, suggesting that MIF in association with 
CD74 and CD44, as a complex, plays a significant 
role in bladder cancer cell proliferation [37]. Similarly, 
Meyer-Siegler et al., reported that the interaction 
between MIF and CD74 activates the ERK1 and 
ERK2 signalling pathway, presumably through 
interaction with CD44, in the prostate cancer cell lines 
DU-145 and LNCaP, but not in normal human 
prostate epithelial cells (PrEC) or benign prostate 
epithelial cells (BPH-1) [34]. However, human benign 
prostate hyperplasia epithelial cells (BPH-1) and PrEC 
prostate cancer cells do not express CD74 on the cell 
surface, so for this reason, both cells do not interact 
with MIF and CD44 [34]. Correspondingly, Shi et al. 
showed that mammalian COS-7 cells do not bind MIF 
unless engineered to express the extracellular domain 
of CD74 [10]. 
To investigate the role of CD74 in apoptosis 
and proliferation, siRNA that targeted CD74 was used. 
Western blot results (Figure 4A and 4B) showed that 
CD74 expression was strongly knocked down in 
CAMA-1 and MDA-MB-231 cells in comparison with 
the control and CD74 siRNA. Microscopic results also 
confirmed that CD74 expression was strongly 
knocked down in both cell lines (Figure 4C and 4D). 
When CD74 expression was knocked down, 
apoptosis was observed in CAMA-1 and MDA-MB-
231 cells. Both cell lines, when treated with CD74 
siRNA, displayed significantly higher levels of annexin 
V staining (± 55% and ± 58% respectively) compared 
to negative control siRNA-treated counterparts (± 8% 
and ± 13% respectively). In the same manner, it was 
found that in CAMA-1 and MDA-MB-231 cells treated 
with CD74 siRNA, a significantly reduced proliferation 
was observed compared to cells treated with the 
negative control siRNA control sequence and 
untreated cells. Likewise, it has been reported that 
knockdown of MIF or CD74 expression by RNA 
interference inhibits DU-145 cell proliferation and 
downstream MIF signalling [34], [38]. It is also 
reported that knockdown of the functional expression 
of MIF markedly decreased H460 cell proliferation and 
induced apoptosis, as seen by augmented expression 
of annexin A5 following treatment of H40 cells by MIF 
siRNA [39]. In particular, Verjans et al. showed that 
anti-MIF and anti-CD74 antibodies potently blocked 
cell proliferation of non-invasive MDA-MB-468 and 
invasive MDA-MB-231 breast cancer cells; however, 
this was not observed in non-tumorous MCF-12A cells 
[40]. This could be explained by the absence of the 
cell-surface portion of CD74 in MCF-12A cells. It is 
also reported that CD74 regulates Fas death receptor 
signaling in lymphomas by decreasing the levels of 
Fas receptors on the cell surface [41]. In the same 
manner, Liu et al., have shown that CD74 promotes 
tumor growth, angiogenesis, and cancer cell 
metastasis in vivo [42]. The effect of CD74 in tumor 
growth and cell proliferation was studied by blocking 
the activity of MIF or CD74 in HEK / CD74 or a renal 
cell carcinoma (Caki-1) cells. The data showed that 
CD74-upregulated vascular endothelial growth factor 
D (VEGF-D) positively regulates the expression of 
cyclin D and E, which results in the promotion of cell 
cycle progression [42]. It was reported that G1 / S 
phase proteins cyclin D and cyclin E, were 
upregulated by CD74 and promoted cell cycle 
progression [6]. The recent finding also showed that 
the expression of CD74 was associated with MIBC / 
high grade of the UCB, while the knockdown of CD74 
attenuated the proliferation, invasion, and 
angiogenesis of HT‑1376 [18]. Figure 6 shows the 
proposed signal transduction pathway of MIF with 
CD74 and CD44.  
In conclusion, it was observed that the 
interaction of MIF with CD74 CD44 could be a 
potential tumor marker for breast cancer cells. 
Moreover, level of co-expression of MIF and CD74 
could be a surrogate marker for the efficacy of anti-
angiogenic drugs, particularly in breast cancer tumors. 
Also, knockdown of CD74 by CD74 siRNA 
significantly reduced CAMA-1 and MDA-MB-231 cell 
proliferation and increased the level of apoptotic cells. 
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